101,648 Shares in Core Laboratories Inc. $CLB Purchased by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC acquired a new position in Core Laboratories Inc. (NYSE:CLB) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 101,648 shares of the oil and gas company’s stock, valued at approximately $1,184,000. Rice Hall James & Associates LLC owned about 0.22% of Core Laboratories at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in CLB. Goldman Sachs Group Inc. lifted its position in shares of Core Laboratories by 185.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 845,251 shares of the oil and gas company’s stock valued at $13,549,000 after acquiring an additional 548,657 shares in the last quarter. Disciplined Growth Investors Inc. MN increased its position in shares of Core Laboratories by 9.7% during the third quarter. Disciplined Growth Investors Inc. MN now owns 5,969,860 shares of the oil and gas company’s stock worth $73,787,000 after purchasing an additional 528,976 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Core Laboratories in the 2nd quarter valued at $4,675,000. MAC Alpha Capital Management LP acquired a new position in Core Laboratories in the 4th quarter valued at $5,016,000. Finally, Heartland Advisors Inc. purchased a new position in Core Laboratories in the 1st quarter valued at $2,518,000. Institutional investors and hedge funds own 97.81% of the company’s stock.

Core Laboratories Price Performance

NYSE:CLB opened at $12.45 on Wednesday. Core Laboratories Inc. has a one year low of $9.79 and a one year high of $20.36. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.55 and a current ratio of 2.12. The stock has a market cap of $570.98 million, a PE ratio of 22.22, a P/E/G ratio of 3.00 and a beta of 1.03. The stock has a 50 day moving average price of $11.57 and a 200 day moving average price of $14.57.

Core Laboratories (NYSE:CLB) last announced its quarterly earnings data on Wednesday, July 29th. The oil and gas company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.02. The firm had revenue of $124.61 million for the quarter, compared to the consensus estimate of $126.26 million. Core Laboratories had a return on equity of 10.03% and a net margin of 5.10%.The firm’s revenue was down 4.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.19 earnings per share. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS. Equities research analysts expect that Core Laboratories Inc. will post 0.53 EPS for the current fiscal year.

Core Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Monday, August 10th will be given a dividend of $0.01 per share. The ex-dividend date of this dividend is Monday, August 10th. This represents a $0.04 annualized dividend and a dividend yield of 0.3%. Core Laboratories’s payout ratio is presently 7.14%.

Wall Street Analyst Weigh In

CLB has been the topic of several recent research reports. Weiss Ratings raised shares of Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, August 3rd. Johnson Rice upgraded shares of Core Laboratories from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a research report on Thursday, August 13th. Finally, Wall Street Zen raised shares of Core Laboratories from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Insider Activity

In other news, CEO Lawrence Bruno acquired 5,000 shares of the company’s stock in a transaction that occurred on Friday, July 31st. The stock was purchased at an average price of $10.78 per share, with a total value of $53,900.00. Following the completion of the acquisition, the chief executive officer owned 262,438 shares of the company’s stock, valued at $2,829,081.64. This trade represents a 1.94% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 1.26% of the company’s stock.

Core Laboratories Profile

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.